Systemic Immunotherapy Effective for Refractory Extramedullary Acute Myeloid Leukemia.
作者信息
Alfayez Mansour, Ivan Doina, Pemmaraju Naveen, Daver Naval, DiNardo Courtney D
机构信息
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
出版信息
JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00198. Epub 2019 Feb 6.
Abstract
摘要
相似文献
1
Systemic Immunotherapy Effective for Refractory Extramedullary Acute Myeloid Leukemia.全身免疫疗法对难治性髓外急性髓系白血病有效。
JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00198. Epub 2019 Feb 6.
2
Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets.免疫检查点抑制剂在急性髓系白血病中的应用：新型联合疗法与治疗靶点
Curr Oncol Rep. 2019 Mar 23;21(4):37. doi: 10.1007/s11912-019-0781-7.
3
Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges.检查点抑制剂与急性髓系白血病：前景与挑战
Expert Rev Hematol. 2018 May;11(5):373-389. doi: 10.1080/17474086.2018.1459184.
4
The emerging role of immune checkpoint based approaches in AML and MDS.基于免疫检查点的方法在急性髓系白血病和骨髓增生异常综合征中的新作用。
Leuk Lymphoma. 2018 Apr;59(4):790-802. doi: 10.1080/10428194.2017.1344905. Epub 2017 Jul 6.
5
Targeting Immune Signaling Checkpoints in Acute Myeloid Leukemia.靶向急性髓系白血病中的免疫信号检查点
J Clin Med. 2019 Feb 12;8(2):236. doi: 10.3390/jcm8020236.
6
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.阿扎胞苷和纳武利尤单抗治疗复发/难治性急性髓系白血病的疗效、安全性和生物标志物：一项非随机、开放标签、Ⅱ期研究。
Cancer Discov. 2019 Mar;9(3):370-383. doi: 10.1158/2159-8290.CD-18-0774. Epub 2018 Nov 8.
7
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.下一代免疫检查点抑制剂：黑色素瘤中的PD-1/PD-L1阻断
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
8
Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes.去甲基化药物与免疫疗法：急性髓系白血病和骨髓增生异常综合征中的治疗协同作用
Front Oncol. 2021 Feb 25;11:624742. doi: 10.3389/fonc.2021.624742. eCollection 2021.
9
Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy.在 PD-1 单药治疗相关肾病综合征发展后，对联合使用伊匹单抗和纳武单抗的反应。
J Immunother Cancer. 2019 Jul 12;7(1):181. doi: 10.1186/s40425-019-0655-4.
10
Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.双功能 PD-1 × αCD3 × αCD33 融合蛋白逆转急性髓系白血病中的适应性免疫逃逸。
Blood. 2018 Dec 6;132(23):2484-2494. doi: 10.1182/blood-2018-05-849802. Epub 2018 Oct 1.
引用本文的文献
1
Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium.纳武单抗联合5-阿扎胞苷治疗儿童复发/难治性急性髓系白血病（AML）：儿童白血病和淋巴瘤治疗进展（TACL）联盟的I/II期试验结果
Cancers (Basel). 2024 Jan 24;16(3):496. doi: 10.3390/cancers16030496.
本文引用的文献
1
Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges.检查点抑制剂与急性髓系白血病：前景与挑战
Expert Rev Hematol. 2018 May;11(5):373-389. doi: 10.1080/17474086.2018.1459184.
2
Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition.伴有核磷蛋白1突变的急性髓系白血病：一种具有免疫原性的急性髓系白血病亚型及免疫检查点抑制的潜在候选对象。
Haematologica. 2017 Dec;102(12):e499-e501. doi: 10.3324/haematol.2017.176461. Epub 2017 Sep 21.
3
Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent.通过靶向PD-1疗法挽救耗竭的CD8 T细胞是依赖CD28的。
Science. 2017 Mar 31;355(6332):1423-1427. doi: 10.1126/science.aaf0683. Epub 2017 Mar 9.
4
Ipilimumab for Patients with Relapse after Allogeneic Transplantation.伊匹单抗用于异基因移植后复发的患者。
N Engl J Med. 2016 Jul 14;375(2):143-53. doi: 10.1056/NEJMoa1601202.
5
Augmenting antitumor immune responses with epigenetic modifying agents.用表观遗传修饰剂增强抗肿瘤免疫反应。
Front Immunol. 2015 Feb 4;6:29. doi: 10.3389/fimmu.2015.00029. eCollection 2015.
6
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.低甲基化剂治疗可增强骨髓增生异常综合征中 PD-L1、PD-L2、PD-1 和 CTLA4 的表达。
Leukemia. 2014 Jun;28(6):1280-8. doi: 10.1038/leu.2013.355. Epub 2013 Nov 25.
7
Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut).针对细胞质NPM1突变区域的免疫反应可能有助于NPM1突变（NPM1mut）的急性髓系白血病患者获得良好的临床结果。
Blood. 2013 Aug 8;122(6):1087-8. doi: 10.1182/blood-2013-04-496844.
8
Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia.核仁磷酸蛋白 1 的突变区域在急性髓系白血病患者中引发 CD4(+)和 CD8(+)T 细胞反应。
Blood. 2012 Aug 9;120(6):1282-9. doi: 10.1182/blood-2011-11-394395. Epub 2012 May 16.
9
Combined Cytosine-arabinoside plus interferon-alpha .2. Clinical-studies in leukemia and lymphoma.阿糖胞苷联合α干扰素。2.白血病和淋巴瘤的临床研究。
Int J Oncol. 1993 Mar;2(3):469-72. doi: 10.3892/ijo.2.3.469.
10
Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.程序性死亡配体 1 表达于非霍奇金淋巴瘤中，可抑制肿瘤相关 T 细胞的活性。
Clin Cancer Res. 2011 Jul 1;17(13):4232-44. doi: 10.1158/1078-0432.CCR-10-2660. Epub 2011 May 3.
Zotero 插件